Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Enhancer RNA transcription defines novel CSF1 enhancer in triple-negative breast cancer

ABSTRACT: Enhancer RNA transcription defines novel CSF1 enhancer in triple-negative breast cancer

PROVIDER: PRJNA768668 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Enhancer RNA transcription defines novel CSF1 enhancer in triple-negative breast cancer

Project description:We report the results of employing CRISPR interference (CRISPRi) to epigenetically perturb the CSF1 transcription start site or novel CSF1 enhancer, followed by high-throughput RNA-sequencing to identify downstream gene expression changes in human triple negative breast cancer cells.

2022-04-12 | GSE185318 | GEO

Epigenomic enhancer profiling defines a signature of colon cancer

Project description:This SuperSeries is composed of the following subset Series: GSE36204: Epigenomic enhancer profiling defines a signature of colon cancer [ChIP-seq] GSE36400: All exon array expression data in normal colon and primary colon cancer lines [expression] Refer to individual Series

2012-04-15 | E-GEOD-36401 | biostudies-arrayexpress

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer

Project description:Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer

| PRJNA705889 | ENA

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

RNAseq of untreated and CSF1-treated, CSF1+QVD-treated monocytes

Project description:Caspases, which are key effectors of apoptosis, have demonstrated non-apoptotic functions. One of these functions is the differentiation into macrophages of peripheral blood monocytes exposed to Colony-Stimulating Factor-1 (CSF1). Macrophage polarization plays an important role in the pathogenesis of diverse human diseases as cancer, leading us to explore if caspase inhibition would affect macrophage polarization. To explore the role of caspases in CSF1 differentiation, we used human monocytes sorted from buffy coats treated by cytokines. We reported that caspase inhibition delays the ex vivo differentiation of peripheral blood monocytes exposed to CSF1 and modifies the phenotype of generated macrophages, e.g. cell shape, surface markers. Moreover, by RNAseq, we observed that the macrophages generated in presence of CSF1 and QVD are different from CSF1-treated monocytes. This study confirms the importance of caspase activation in CSF1 differentiation.

2024-01-01 | E-MTAB-8088 | biostudies-arrayexpress

Metastasis in triple-negative breast cancer

Project description:Metastasis in triple-negative breast cancer

| PRJNA437929 | ENA

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Project description:This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

| 2007227 | ecrin-mdr-crc

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [CRISPR]

Project description:Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [CRISPR]

| PRJNA705890 | ENA

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [RNA_seq]

Project description:Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [RNA_seq]

| PRJNA705891 | ENA

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [ChIP_seq]

Project description:Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [ChIP_seq]

| PRJNA705892 | ENA